In 2022, imports accounted for 55 percent of the pharmaceutical market in Vietnam. In that year, the total value of the pharmaceutical market in the country reached ***** trillion Vietnamese dongs.

In 2021, the hospital channel accounted for ** percent of the pharmaceutical market in terms of value in Vietnam. Due to the COVID-19 pandemic, the revenue of pharmaceuticals via hospital channels decreased while the revenue via pharmacies increased in that year.

The Vietnam oral anti-diabetic drug market is experiencing robust growth, projected to reach $156.21 million in 2025 and maintain a Compound Annual Growth Rate (CAGR) exceeding 4.00% from 2025 to 2033. This expansion is fueled by several key factors. Rising prevalence of diabetes in Vietnam, driven by increasing urbanization, sedentary lifestyles, and changing dietary habits, is a primary driver. The growing awareness of diabetes management and the increasing accessibility of affordable oral medications are also contributing to market growth. Furthermore, the increasing geriatric population further amplifies the demand for these life-sustaining drugs. The market is segmented based on drug class (e.g., sulfonylureas, biguanides, DPP-4 inhibitors, SGLT2 inhibitors), with the specific market share of each segment influenced by factors like efficacy, side effect profiles, and pricing. Key players like Merck & Co, Pfizer, Takeda, and others are actively competing in this market through product innovation, strategic partnerships, and focused marketing efforts. Government initiatives to improve healthcare access and affordability are also likely to contribute to the market's continued expansion. Despite the positive outlook, challenges remain. The market faces potential restraints from the high cost of advanced therapies, the need for improved patient education and adherence to treatment regimens, and the potential emergence of generic competition. However, the continued investment in healthcare infrastructure and the ongoing efforts to improve diabetes prevention and management should mitigate these challenges to a significant degree, ensuring substantial market growth in the years to come. This robust growth signifies a promising investment opportunity in Vietnam's expanding pharmaceutical sector. Key drivers for this market are: Increasing Geriatric Population and Changing Dietary Habits, High Prevalence of Irritable bowel syndrome with constipation (IBS-C) and Opioid-induced constipation (OIC) and Chronic Constipation; Development of Latest Drugs and Treatment Procedures. Potential restraints include: Increasing Dependence on Majority of Over-the-Counter (OTC) Drugs, Lack of Awareness and Reluctance Among Patients due to Adverse Effects of Opioid-Induced Constipation (OIC) Drugs. Notable trends are: Sulfonylureas Segment Occupied the Highest Market Share in the Vietnam Oral Anti-Diabetic Drugs Market in the current year..

In 2022, OTC drugs accounted for ** percent of the pharmaceutical market in Vietnam. Ethical medicines, or medicine prescribed by a doctor, made up the majority of the pharmaceutical market in the same year. According to the source, Vietnam's pharmaceutical market value was about ***** trillion Vietnamese dong in that year.

Forecast: Pharmaceutical Goods Market Size Value in Vietnam 2024 - 2028 Discover more data with ReportLinker!

Pharmaceutical Goods Market Size Value Per Capita in Vietnam, 2023 Discover more data with ReportLinker!

Vietnam Chemical Pharmaceutical Market is expected to grow during 2025-2031

Pharmaceuticals in Dosage Market Size Value in Vietnam, 2023 Discover more data with ReportLinker!

The report covers Diabetes Care Drugs in Vietnam and is segmented by drugs (oral anti-diabetic drugs, insulin, non-insulin injectable drugs, and combination drugs).

The Vietnam Oral Anti-Diabetic Drug Market Report is Segmented by Drug Class (Biguanides, Sulfonylureas, Meglitinides, Thiazolidinediones, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, SGLT-2 Inhibitors, Others), Age Group (Adults, Pediatric, Geriatric), Diabetes Type (Type 1, Type 2), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies). The Market Forecasts are Provided in Terms of Value (USD).

Vietnam Pharmaceutical Filtration Market is valued at USD 60 million, driven by biopharmaceutical demand, regulatory standards, and advanced technologies like ultrafiltration.

Vietnam Over-the-Counter (OTC) Drugs Market was valued at USD 2.11 Million in 2023 and is expected to reach USD 2.92 Million by 2029 with a CAGR of 5.50% during the forecast period.

Vietnam Pharmaceutical Intermediates Market growth is driven by increasing demand for generics, advancements in chemical synthesis technologies, and outsourcing by pharmaceutical companies.

Pharmaceutical Goods Market Size Value in Vietnam, 2021 Discover more data with ReportLinker!

In 2019, Duoc Hau Giang (DHG) Pharmaceutical JSC generated a sales revenue of *** trillion Vietnamese dong. DHG is one of the largest pharmaceutical companies in Vietnam and is engaged in the manufacturing and selling of over-the-counter (OTC) medicines. In April 2019, DHG became a subsidiary of Taisho Pharmaceutical Co. Ltd. In that year, the market size of pharmaceuticals in Vietnam was estimated at about ***** trillion Vietnamese dong.

Discover the emerging Vietnam Myotonic Dystrophy Type 1 (DM1) market. This analysis projects market size, growth rate, and key trends, offering valuable insights for healthcare professionals and investors in this underserved area. Explore regional market shares and future growth opportunities.

The Vietnam insulin drug and delivery device market is experiencing robust growth, driven by rising prevalence of diabetes, an aging population, and increasing healthcare expenditure. The market, valued at approximately $X million in 2025 (assuming a logical market size based on comparable developing nations and the provided CAGR), is projected to maintain a Compound Annual Growth Rate (CAGR) exceeding 2.00% through 2033. This growth is fueled by several factors including improved diagnosis rates, increased awareness of diabetes management, and greater access to modern insulin therapies. The market segmentation reveals significant demand for various insulin types, including basal/long-acting insulins (like Lantus, Levemir, and their biosimilars), bolus/fast-acting insulins (such as NovoRapid and Humalog), and insulin combinations. The increasing adoption of insulin delivery devices, such as insulin pens and pumps, contributes significantly to market expansion. This trend is propelled by the convenience, precision, and improved patient compliance these devices offer compared to traditional syringes. However, challenges such as high cost of insulin therapies, limited healthcare infrastructure in certain regions, and affordability concerns might act as restraints on market growth. The competitive landscape involves major pharmaceutical companies like Novo Nordisk, Sanofi, Eli Lilly, and others, each striving to capture market share through innovative product launches and strategic partnerships. The market's future trajectory hinges on government initiatives to improve diabetes management programs, wider insurance coverage for insulin therapies, and increased public awareness campaigns. Further growth is anticipated from the expanding biosimilar insulin segment, offering more affordable treatment options. The introduction of technologically advanced insulin delivery systems, including smart insulin pens and connected insulin pumps, promises to further enhance patient outcomes and drive market expansion in the coming years. Continued monitoring of the healthcare infrastructure development within Vietnam will be crucial in accurately forecasting market performance. The rising adoption of telehealth and remote patient monitoring could also play a significant role in influencing market growth, enabling efficient diabetes management, particularly in rural areas. Recent developments include: March 2023: A memorandum of understanding (MoU) was signed between the Administration of Medical Service under the Ministry of Health, the Vietnam Association of Diabetes and Endocrinology, and the French pharmaceutical company Sanofi Vietnam to cooperate on the implementation of the online training program on diabetes treatment and management, iSTEP-D Plus Online., June 2022: France-based Sanofi-Aventis Vietnam and local pharmacy chain FPT Long Chau signed a Memorandum of Understanding on cooperation to implement their 'Insulin Pen Sustainability Pilot Project' on plastic waste reduction.. Notable trends are: Insulin Devices is Having the Highest volume Share in Current Year.

The global pharmaceutical market is expected to grow at a CAGR of 5% during 2011-2017, exceeding sales worth US$ 1.1 Trillion by 2017. This market, however, is expected to undergo a number of transitions which would impact the course of its growth. These transitions include a shift of growth from the developed to the emerging markets, an increasing focus on biopharmaceuticals compared to small molecule drugs and an increasing preference for generics compared to their branded versions. As a result of these transformations; the need for a user friendly, robust and comprehensive pharmaceutical market intelligence has become imperative for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the pharmaceutical market in some form or the other.

IMARC Group, one of the world’s leading research and advisory firms, introduces a new and revolutionary way to understand and evaluate the global pharmaceutical market with its Microsoft Excel based report entitled “Global Pharmaceutical Market Report & Forecast: 2012-2017”. This report provides an analytical and statistical insight into the global pharmaceutical market. The study, which has been undertaken using desk based as well as primary market research has analyzed the following aspects of the global pharmaceutical market.

What We Have Achieved in This Report?

Regions Covered: Global, North America, Europe, Asia Pacific, Latin America & Caribbean and Middle East & Africa

Countries Covered in Each Region

North America: United States and Canada

Europe: Germany, France, Italy, Spain, United Kingdom, Russia, Turkey, Netherlands, Poland, Greece, Belgium, Switzerland, Austria, Sweden, Portugal, Hungary, Romania, Denmark, Czech Republic, Finland, Ireland, Norway, Slovakia, Bulgaria, Croatia, Slovenia, Lithuania, Latvia, Luxembourg and Estonia

Asia Pacific: Japan, China, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Pakistan, Vietnam, Bangladesh, Hong Kong, New Zealand, Malaysia and Singapore

Latin America & Caribbean:Brazil, Mexico, Venezuela, Argentina, Puerto Rico, Colombia, Chile, Ecuador, Peru, Dominican Republic and Uruguay

Middle East & Africa: South Africa, Egypt, Saudi Arab, Algeria, Morocco, United Arab Emirates Lebanon, Tunisia, Jordan and Kuwait

Focus of the Analysis:

• Historical sales performance (2007-2011) for each country
• Historical sales performance (2007-2011) for each region
• Sales forecast (2012-2017) for each country
• Sales forecast (2012-2017) for each region
• Sales performance of key manufacturers for each country (2007-2011)
• Sales performance of key therapeutic areas for each country (2007-2011)
• Country wise sales breakup for each region (2007-2011)
• Country wise sales breakup forecast for each region (2012-2017)

Key Questions Answered;

• What was the historical performance of the global pharmaceutical market?
• Which are the key regions and countries in the global pharmaceutical market?
• Which are the largest pharmaceutical markets in the world?
• Which are the fastest growing pharmaceutical markets in the world?
• Which markets are expected to witness the slowest growth in the coming years?
• Which countries represent the key markets for each region?
• What has been the performance of various therapeutic classes in each country?
• Who are the top pharmaceutical manufacturers in each country?
• What are the market shares of the top pharmaceutical manufacturers in each country?

Why You should Buy This Report?

• To gain a comprehensive understanding on the historical, current and future pharmaceutical market trends across 70 countries in 6 regions.
• To identify potential regions, countries, therapeutic areas, partners and competitors for market entry and expansion plans.
• As a tool for developing investment strategies by identifying the biggest winners and losers across various regions and countries.
• To ensure a successful M&A and partnership strategy by identifying therapeutic areas and companies with the most promising outlook.

The value of Thailand's pharmaceutical market amounted to around *** billion Thai baht in 2023, making it the third-biggest market in Southeast Asia. The market is expected to reach *** billion Thai baht in 2024. Pharmaceuticals market in Thailand The Ministry of Public Health regulates pharmaceuticals in Thailand. Despite the low spending per person on drugs, the market was still expected to expand, resulting in a forecasted rise in the share of pharmaceutical sales as a part of GDP. Antibiotics were the leading pharmaceuticals exported from Thailand. The leading exporting destinations for Thailand for pharmaceuticals and medical supplies are Vietnam, Myanmar, and Cambodia.

Pharmaceutical manufacturing industry in Thailand Since medicine costs are a major expense borne by the public health system, the modern pharmaceutical manufacturing industry is one of the most important industries in Thailand. Thailand issued almost *** pharmaceutical licenses for manufacturing modern medicine in 2022. Pharmaceutical solutions and tablets were the major pharmaceutical products produced in the country, with over **** metric tons manufactured as of May 2023.

The size of the Vietnam Diabetes Drugs Market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 3.70% during the forecast period. Recent developments include: December 2022: Viatris announced the expansion of an existing partnership with Cypriot pharmaceutical company Medochemie, which aimed to boost drug production in Vietnam and improve patients' access to locally made medicines there. Specifically, Viatris was expected to transfer the technology that Medochemie was to use under license to make certain drugs from Viatris' noncommunicable disease portfolio., August 2022: Vietnam declared that'Hạ An Đường' does not cure diabetes. The product packaged as Vietnamese Hạ An Đường was believed to cure diabetes and was not on the Philippine Food and Drug Administration's (FDA) list of approved drugs and food products.. Key drivers for this market are: Increasing Geriatric Population and Changing Dietary Habits, High Prevalence of Irritable bowel syndrome with constipation (IBS-C) and Opioid-induced constipation (OIC) and Chronic Constipation; Development of Latest Drugs and Treatment Procedures. Potential restraints include: Increasing Dependence on Majority of Over-the-Counter (OTC) Drugs, Lack of Awareness and Reluctance Among Patients due to Adverse Effects of Opioid-Induced Constipation (OIC) Drugs. Notable trends are: Oral-Anti Diabetes Drugs is Having the Highest Market Share in the Current Year..